Scientific Opinion on the substantiation of health claims related to resistant maltodextrin and reduction of post-prandial glycaemic responses (ID 796), maintenance of normal blood LDL-cholesterol concentrations (ID 2927), maintenance of normal (fasting) blood concentrations of triglycerides (ID 2927) and changes in bowel function (ID 797) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
Articolo
Data di Pubblicazione:
2011
Citazione:
Scientific Opinion on the substantiation of health claims related to resistant maltodextrin and reduction of post-prandial glycaemic responses (ID 796), maintenance of normal blood LDL-cholesterol concentrations (ID 2927), maintenance of normal (fasting) blood concentrations of triglycerides (ID 2927) and changes in bowel function (ID 797) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 / C.V. Agostoni, J.L. Bresson, S. Fairweather Tait, A. Flynn, I. Golly, H. Korhonen, P. Lagiou, M. Løvik, R. Marchelli, A. Martin, B. Moseley, M. Neuhäuser Berthold, H. Przyrembel, S. Salminen, Y. Sanz, S. Strain, S. Strobel, I. Tetens, D. Tomé, H. van Loveren, H. Verhagen. - In: EFSA JOURNAL. - ISSN 1831-4732. - 9:4(2011 Apr), pp. 2070.1-2070.17. [10.2903/j.efsa.2011.2070]
Abstract:
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to resistant maltodextrin and reduction of post-prandial glycaemic responses, maintenance of normal blood LDL-cholesterol concentrations, maintenance of normal (fasting) blood concentrations of triglycerides and changes in bowel function. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.
The food constituent that is the subject of the health claims is resistant maltodextrin. The Panel considers that resistant maltodextrin is sufficiently characterised in relation to the claimed effects.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Resistant maltodextrin ; glycaemic responses ; LDL-cholesterol ; triglycerides ; bowel function ; health claims
Elenco autori:
C.V. Agostoni, J.L. Bresson, S. Fairweather Tait, A. Flynn, I. Golly, H. Korhonen, P. Lagiou, M. Løvik, R. Marchelli, A. Martin, B. Moseley, M. Neuhäuser Berthold, H. Przyrembel, S. Salminen, Y. Sanz, S. Strain, S. Strobel, I. Tetens, D. Tomé, H. van Loveren, H. Verhagen
Link alla scheda completa: